Related Experiment Video
Updated: Nov 5, 2025
09:12
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
10.3K
Immune response against Clostridioides difficile and translation to therapy
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Therapeutic Advances in Gastroenterology
|May 17, 2021
Summary
Bezlotoxumab, a monoclonal antibody targeting Clostridioides difficile toxin B, effectively reduced recurrent infections, especially in high-risk patients. Actoxumab showed no significant benefit, highlighting bezlotoxumab
Area of Science:
- Immunology
- Microbiology
- Infectious Diseases
Background:
- Clostridioides difficile infection (CDI) pathogenesis is primarily linked to toxins A and B.
- Recurrent CDI poses a significant clinical challenge, necessitating novel therapeutic strategies.
- Systemic humoral immunity against these toxins can confer protection against recurrence.
Purpose of the Study:
- To evaluate the efficacy of monoclonal antibodies targeting C. difficile toxins A and B in preventing recurrent CDI.
- To assess the therapeutic benefit of actoxumab (anti-toxin A) and bezlotoxumab (anti-toxin B) in clinical trials.
Main Methods:
- Clinical trials were conducted to assess the efficacy of fully human monoclonal antibodies against C. difficile toxins.
- Patients received either actoxumab or bezlotoxumab to evaluate their impact on recurrent CDI rates.
Main Results:
- Bezlotoxumab demonstrated a substantial reduction in the rate of recurrent CDI.
- Actoxumab did not show a significant therapeutic benefit in preventing recurrent infections.
- A notable therapeutic advantage of bezlotoxumab was observed in patients with high-risk factors for recurrence (e.g., age ≥65, immunocompromised, prior CDI, severe CDI).
Conclusions:
- Bezlotoxumab is an effective therapeutic option for reducing recurrent Clostridioides difficile infections, particularly in at-risk populations.
- Monoclonal antibody-based therapies targeting specific toxins represent a promising approach for managing recurrent CDI.
- Ongoing vaccine trials targeting C. difficile toxins aim to prevent primary infections, complementing antibody-based strategies.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
277
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
277
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
300
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
300
01:29Inflammatory Bowel Disease IV: Pharmacological Management
258
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
258
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
266
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
266
01:16Transduction
453
Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome...
453
01:31Defense Against Bacterial Pathogens
1.7K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.7K